Compare Gilead Sciences, Inc. (GILD) vs Quantum Computing Inc (QUBT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Quantum Computing Inc — how do they compare? Gilead Sciences, Inc. trades at $133.72 (market cap $163.51B), while Quantum Computing Inc trades at $7.66 (market cap $1.81B). The key difference: Gilead Sciences, Inc. is far larger — about 90.3× Quantum Computing Inc's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Quantum Computing Inc pays none. Which is the better fit depends on your goals.
| GILD | QUBT | |
|---|---|---|
Market Cap | $163.51B | $1.81B |
Sector | Health | Technology |
52-Week High | $155.80 | $24.62 |
52-Week Low | $108.22 | $6.31 |
Enterprise Value | $178.05B | $830.89M |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Quantum Computing Inc. (QUBT) trades at $7.81, down 6.13% today amid broader quantum stock weakness. The stock shows bearish technical signals with negative moving averages but oversold RSI conditions. Fundamentally, QUBT reports minimal revenue of $682K (2025) with significant losses (-$18.67M net income) and negative margins, though recent earnings beat expectations. Analyst sentiment remains bullish with a $24 consensus target representing 207% upside potential, supported by strategic acquisitions and quantum commercialization progress.
QUBT offers speculative growth potential in quantum computing but carries substantial risk due to heavy cash burn (-$30M operating cash flow) and unproven commercial scalability. The company's survival depends on continued financing and successful technology commercialization. While analyst optimism and policy tailwinds provide catalysts, investors face binary outcomes between breakthrough success and financial distress in this capital-intensive sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Quantum Computing Inc
Quantum Computing Inc. is a company focused on providing accessible quantum computing and quantum-enhanced software solutions for complex problems. The company's technology is designed to run on both classical and quantum hardware, enabling businesses to explore the power of quantum computing today for applications in finance, drug discovery, and logistics. QUBT offers a platform that makes quantum algorithms and software available through the cloud, aiming to democratize access to this advanced computing paradigm.
Read more on QUBT →
